Triazolam 0.25 MG Oral Tablet for Anxiety

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Anxiety
Triazolam 0.25 MG Oral Tablet - Drug
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

This trial will attempt to identify if there is a relationship between vestibular signals and anxiety by studying the effects of two different drugs known to reduce the theta rhythm.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 1 Secondary · Reporting Duration: Derived from EEGs recorded for 30-45 mins

Derived from EEGs recorded for 30-45 mins
EEG power spectrum
Signal correlations
Derived from EEGs recorded for 30-45 mins.
4-12 Hz modulation

Trial Safety

Safety Progress

1 of 3

Trial Design

3 Treatment Groups

Triazolam
1 of 3
Buspirone
1 of 3
Placebo
1 of 3
Experimental Treatment
Non-Treatment Group

42 Total Participants · 3 Treatment Groups

Primary Treatment: Triazolam 0.25 MG Oral Tablet · Has Placebo Group · N/A

Triazolam
Drug
Experimental Group · 1 Intervention: Triazolam 0.25 MG Oral Tablet · Intervention Types: Drug
Buspirone
Drug
Experimental Group · 1 Intervention: Buspirone 10 Mg Oral Tablet · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo oral tablet · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: derived from eegs recorded for 30-45 mins

Who is running the clinical trial?

University of ManitobaLead Sponsor
537 Previous Clinical Trials
186,887 Total Patients Enrolled
8 Trials studying Anxiety
576 Patients Enrolled for Anxiety

Eligibility Criteria

Age 18 - 65 · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 8th, 2021

Last Reviewed: October 20th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.